Product Description
Emraclidine is an orally available muscarinic M4 Receptor (PAM) being investigated for the treatment of schizophrenia and other forms of psychosis. (Sourced from: https://www.abbvie.com/science/pipeline.html)
Mechanisms of Action: M4 PAM
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: Eastern America
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Bulgaria, Hungary, Puerto Rico, Ukraine, United States
Active Clinical Trial Count: 17
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psychotic Disorders
Phase 1: Alzheimer Disease|Healthy Volunteers|Kidney Diseases|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05940402 |
CVL-231-SP-1007 | P1 |
Completed |
Kidney Diseases |
2024-12-19 |
50% |
2025-03-06 |
|
NCT05935033 |
CVL-231-SP-1008 | P1 |
Completed |
Other |
2025-02-21 |
50% |
2025-03-06 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2024-511441-19-00 |
CVL-231-2003 | P2 |
Active, not recruiting |
Schizophrenia |
2026-02-28 |
2025-05-02 |
Treatments |
|
NCT05227690 |
CVL-231-2001 | P2 |
Completed |
Schizophrenia|Psychotic Disorders |
2024-08-23 |
12% |
2025-09-18 |
Primary Endpoints|Treatments |
NCT05644977 |
CVL-231-1006 | P1 |
Completed |
Alzheimer Disease |
2025-04-14 |
50% |
2025-05-03 |
Primary Endpoints |
NCT05933187 |
CVL-231-HV-1013 | P1 |
Completed |
Healthy Volunteers |
2023-09-12 |
23% |
2023-11-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT05915546 |
CVL-231-HV-1009 | P1 |
Completed |
Healthy Volunteers |
2023-07-26 |
69% |
2023-11-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT04787302 |
CVL-231-1002 | P1 |
Completed |
Schizophrenia |
2023-07-14 |
48% |
2023-07-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07145918 |
M25-522 | P2 |
Recruiting |
Schizophrenia |
2028-02-01 |
12% |
2025-08-29 |
|
NCT05443724 |
CVL-231-2003 | P2 |
Completed |
Schizophrenia |
2025-06-25 |
12% |
2025-07-29 |
Primary Endpoints |
2022-000581-17 |
2022-000581-17 | P2 |
Completed |
Schizophrenia |
2024-09-11 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2022-000580-52 |
2022-000580-52 | P2 |
Completed |
Schizophrenia |
2024-08-26 |
12% |
2025-05-06 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT05227703 |
CVL-231-2002 | P2 |
Completed |
Schizophrenia |
2024-08-15 |
50% |
2024-12-21 |
|
NCT07219030 |
M25-904 | P1 |
Recruiting |
Healthy Volunteers |
2026-11-01 |
88% |
2025-10-23 |
|
NCT06366243 |
CVL-231-HV-1012 | P1 |
Completed |
Healthy Volunteers |
2024-06-20 |
12% |
2024-07-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06301971 |
CVL-231-HV-1011 | P1 |
Completed |
Healthy Volunteers |
2024-04-04 |
50% |
2024-05-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT05965219 |
CVL-231-HV-1010 | P1 |
Completed |
Healthy Volunteers |
2023-11-10 |
23% |
2024-04-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |